Abducens nerve palsy during pegvisomant therapy in an acromegalic patient


Pegvisomant is a recent treatment modality of acromegaly, which is most effective in regulating IGF-1 levels. Tumor growth has been reported in 5% of the acromegaly cases treated with pegvisomant. Herein we report a case of acromegaly resistant to surgical treatment, radiotherapy and medical therapy with a somatostatin analogue and cabergolin. Due to presence of pituitary tumor with cavernous sinus invasion and unremitting disease activity pegvisomant therapy was initiated. She developed left abducens nerve palsy after pegvisomant treatment. The objective of this report is to emphasize the value of close follow-up of the acromely cases under pegvisomant therapy, especially if they have cavernous sinus infiltrating tumor. A 44-year-old woman with acromegaly presented with visual defect and diplopia on left lateral gaze. Her complaint developed 3 years after initiation of pegvisomant therapy. Her neurologic examination was consistent with mild abducens nerve palsy on left side. Other causes for abducens nerve palsy were excluded. Pegvisomant was discontinued upon patient request. Although sella MRI did not reveal a tumor growth, even minimal growth within cavernous sinus can cause cranial nerve involvement. Therefore close and careful follow-up of cavernous sinus infiltrating tumors after pegvisomant therapy is crucial to early recognition of complications.

Share and Cite:

Hatipoglu, E. , Kepicoglu, H. , Basar, E. , Gazioglu, N. , Islak, C. , Saip, S. and Kadioglu, P. (2013) Abducens nerve palsy during pegvisomant therapy in an acromegalic patient. Open Journal of Internal Medicine, 3, 66-69. doi: 10.4236/ojim.2013.32017.

Conflicts of Interest

The authors declare no conflicts of interest.


[1] Ben-Shlomo, A. and Melmed, S. (2008) Acromegaly. Endocrinology Metabolism Clinics of North America, 37, 101-122. doi:10.1016/j.ecl.2007.10.002
[2] Bondanelli, M., Ambrasio, M.R. and Degli Uberti, E.C. (2001) Pathogenesis and prevalence of hypertension in acromegaly. Pituitary, 4, 239-249. doi:10.1023/A:1020798430884
[3] Colao, A., Ferone, D., Marzullo, P. and Lombardi, G. (2004) Systemic complications of acromegaly: Epidemiology, pathogenesis, and management. Endocrine Reviews, 25, 102-150. doi:10.1210/er.2002-0022
[4] Fatti, L.M., Scacchi, M., Pincelli, A.I., Lavezzi, E. and Cavagnini, F. (2001) Prevalence and pathogenesis of sleep apnoea in acromegaly. Pituitary, 4, 259-262. doi:10.1023/A:1020702631793
[5] Clemmons, D.R., Van Wyk, J.J., Ridgway, E.C., Kliman, B., Kjellberg, R.N. and Underwood, L.E. (1979) Evaluation of acromegaly by radio immuno assay of somatomedin-C. The New England Journal of Medicine, 301, 1138-1142. doi:10.1056/NEJM197911223012102
[6] Stoffel-Wagner, B., Springer, W., Bidlingmaier, F. and Klingmüller, D. (1997) A comparison of different methods for diagnosing acromegaly. Clinical Endocrinology, 46, 531-537. doi:10.1046/j.1365-2265.1997.1430983.x
[7] Van der Lely, A.J., Hutson, R.K., Trainer, P.J., Besser, G.M., Barkan, A.L., Katznelson, L., Klibanski, A., Herman-Bonert, V., Melmed, S., Vance, M.L., Freda, P.U., Stewart, P.M., Friend, K.E., Clemmons, D.R., Johannsson, G., Stavrou, S., Cook, D.M., Phillips, L.S., Strasburger, C.J., Hackett, S., Zib, K.A., Davis, R.J., Scarlett, J.A. and Thorner, M.O. (2001) Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist. Lancet, 358, 1754-1759. doi:10.1016/S0140-6736(01)06844-1
[8] van der Lely, A.J., Biller, B.M., Brue, T., Buchfelder, M., Ghigo, E., Gomez, R., Hey-Hadavi, J., Lundgren, F., Rajicic, N., Strasburger, C.J., Webb, S.M. and Koltowska-Haggstrom, M. (2012) Long-term safety of pegvisomant in Patients with acromegaly: Comprehensive review of 1288 subjects in acrostudy. The Journal of Clinical Endocrinology & Metabolism, 97, 1589-1597. doi:10.1210/jc.2011-2508?
[9] Buchfelder, M., Weigel, D., Droste, M., Mann, K., Saller, B., Brübach, K., Stalla, G.K., Bidlingmaier, M., Strasburger, C.J. and Investigators of German Pegvisomant Observational Study (2009) Pituitary tumor size in acromegaly during pegvisomant treatment: Experience from MR re-evaluations of the German pegvisomant observational study. European Journal of Endocrinology, 161, 27-35. doi:10.1530/EJE-08-0910
[10] Bonert, V.S., Kennedy, L., Petersenn, S., Barkan, A., Carmichael, J. and Melmed, S. (2008) Lipodystrophy in patients with acromegaly receiving pegvisomant. Journal of Clinical Endocrinology & Metabolism, 93, 3515. doi:10.1210/jc.2008-0833
[11] Buyuktas, D., Celik, O., Kantarci, F. and Kadioglu, P. (2010) Lipodystrophy during pegvisomant therapy: A case report and review of the literature. Clinics (Sao Paulo), 65, 931-933. doi:10.1590/S1807-59322010000900018
[12] Petrovich, Z., Yu, C., Giannotta, S.L., Zee, C.S. and Apuzzo, M.L. (2003) Gamma knife radio surgery for pituitary adenoma: Early results. Neurosurgery, 53, 51-61. doi:10.1227/01.NEU.0000068702.00330.47
[13] Vaphiades, M.S., Spencer, S.A., Riley, K., Francis, C., Deitz, L. and Kline, L.B. (2011) Radiation-induced ocular motor cranial nerve palsies in patients with pituitary tumor. Journal of Neuro-Ophthalmology, 31, 210-213. doi:10.1097/WNO.0b013e31820eb7bc
[14] Cifarelli, C.P., Schlesinger, D.J. and Sheehan, J.P. (2012) Cranial nerve dysfunction following gamma knife surgery for pituitary adenomas: Long-term incidence and risk factors. Journal of Neurosurgery, 116, 1304-1310. doi:10.3171/2012.2.JNS111630

Copyright © 2023 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.